Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 20/20 | 1.00 |
| ▸ | BPTF | Q12830 | 1/20 | 1.00 |
| ▸ | KAT2A | Q92830 | 1/20 | 1.00 |
| ▸ | SETDB1 | Q15047 | 2/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26548080 | 1.00 | KAT2B (1.00) | KAT2BBPTFKAT2ASETDB1 | |
| SCHEMBL29413001 | 0.83 | KAT2B (1.00) | KAT2BBPTFKAT2ASETDB1 | |
| SCHEMBL26793287 | 0.75 | KAT2B (0.59) | KAT2BBPTFKAT2ASETDB1 | |
| SCHEMBL28438090 | 0.72 | KAT2B (1.00) | KAT2BBPTFKAT2ASETDB1 | |
| SCHEMBL28438091 | 0.72 | KAT2B (1.00) | KAT2BBPTFKAT2ASETDB1 | |
| SCHEMBL29413030 | 0.65 | BPTF (0.46) | KAT2BBPTFKAT2A | |
| SCHEMBL28435004 | 0.65 | BPTF (0.46) | KAT2BBPTFKAT2A | |
| SCHEMBL28431573 | 0.64 | NPC1 (0.52) | KAT2BBPTFKAT2A | |
| SCHEMBL29413023 | 0.59 | KAT2B (0.49) | KAT2BSETDB1 | |
| SCHEMBL24870219 | 0.57 | ACACB (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250122502-A1 | Bifunctional Molecules and Methods of Using Thereof | FLAGSHIP PIONEERING, INC. (US) | 2025-04-17 | — | — | US | disclosed |
| US-20230332145-A1 | BIFUNCTIONAL MOLECULES AND METHODS OF USING THEREOF | FLAGSHIP PIONEERING, INC. (US) | 2023-10-19 | — | — | US | disclosed |
| CN-115887668-A | Application of composition or inhibitor for controlling KIF15 gene expression | 广州希灵生物科技有限公司 | 2023-04-04 | — | — | CN | disclosed |
| CN-111499639-B | Pyrimidone derivatives and their use in pharmacy | 四川大学华西医院 | 2022-03-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230332145-A1 | BIFUNCTIONAL MOLECULES AND METHODS OF USING THEREOF | EFTUD2, DDX21, SNRPE | KAT2B 3350/4885BPTF 742/4885KAT2A 2590/4885 |
| US-20250122502-A1 | Bifunctional Molecules and Methods of Using Thereof | EFTUD2, DDX21, SNRPE | KAT2B 3350/4885BPTF 742/4885KAT2A 2590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.